Nanoparticle Based Delivery of miRNAs to Overcome Drug Resistance in Breast CancerYalcin S1* and Gunduz U2
- *Corresponding Author:
- Serap Yalcin
Department of Molecular Biology and Genetics
Faculty of Science and Art
Ahi Evran University
Tel: 90386 280 42 00
E-mail: [email protected]
Received date: December 05, 2016; Accepted date: December 22, 2016; Published date: December 27, 2016
Citation: Yalcin S, Gunduz U (2016) Nanoparticle Based Delivery of miRNAs to Overcome Drug Resistance in Breast Cancer. J Nanomed Nanotechnol 7:414. doi: 10.4172/2157-7439.1000414
Copyright: © 2016 Yalcin S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Nanoparticle-based targeted drug delivery is a successful strategy to overcome the side effect of chemotherapy. Nanoparticles based drug delivery systems that have been designed to enhance delivery of therapeutics to tumors, are a novel approach. Nanoparticles have reactive surface that can be readily modified with biocompatible coatings and loaded with therapeutic agents (miRNA, siRNA, antibody, anti-cancer drug etc..). MicroRNAs (miRNAs or miRs) are short non-coding RNAs which posttranscriptionally regulate growth, differentiation, apoptosis, motility, and malignant transformation. In addition, some miRNAs have been classified as proto-oncogenes. The levels of changed miRNA expression play significant role in the initiation of many diseases, including cancer, especially tumor progression and metastasis. Further studies, miRNA conjugation to drug carrier systems is used to target to cancer cells. In this review, we focus on miRNA carrier nanoparticles, and summarize novel advances about their use in drug resistance breast cancer therapy.